The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
The placebo response is a major issue in clinical trials for psychiatric disorders. Possible contributing factors to this problem include diagnostic misclassification, issues concerning inclusion/exclusion criteria, outcome measures’ lack of sensitivity to change, measurement errors, poor quality of data entry and verification, waxing and waning of the natural course of illness, regression toward the mean phenomenon, patient and clinician expectations about the trial, study design issues, non-specific therapeutic effects, and high attrition. Over the past few decades, researchers have attempted to reduce the placebo effect in a variety of ways. Unfortunately, approaches with very little or no benefit have included restricting enrollment to selected populations, rater training, requirement of same rater, and placebo lead-in phases. Some benefits, although often marginal, have been derived from standardizing diagnostic procedures, managing clinicians’ overestimation of change, simplification of study visits and assessments, minimizing non-specific, therapeutic effects, extending trial duration, reducing number of sites, increasing the sensitivity of outcome measures, and reducing the number of treatment arms. Thus far, there has been no attempt to develop new study designs aimed at reducing the placebo effect. We are proposing a novel study design, called ‘Sequential Parallel Comparison Design’, suitable for double-blind, placebo-controlled trials in psychiatric disorders. This design is aimed at reducing both the overall placebo response rate and the sample size required for such trials. Its usefulness in clinical research needs to be tested empirically. If this study design were to be found to meet its stated goals, this could markedly facilitate the process of clinical development of new compounds for the treatment of psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strategies to mitigate placebo response include increasing study duration, randomizing the run-in period, and addressing functional blinding in rapid-acting antidepressant trials [162]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [162]
Citations
Cites
Linear Statistical Inference and its Applications: Second Editon
Rao, C. R. (1973) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316436 · Cited by 10,489
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“These numbers are even more impressive as most negative trials are typically unpublished, suggesting that the average placebo response rate in MDD trials is probably closer to the 35–45p range.Similarly, in smoking cessation trials, the placebo response rate has progressively increased. For example, in a recent study…”
ResultIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
A Primer on Regression Artifacts
Campbell, D. T., & Kenny, D. A. (1999) · Medical Entomology and Zoology · Cited by 482
Hypericum Depression Trial Study Group (2002) · JAMA · doi:10.1001/jama.287.14.1807 · Cited by 480
Linear Statistical Inference and its Applications.
Moore, P. G., & Rao, C. R. (1967) · The Statistician · doi:10.2307/2987205 · Cited by 439
Rush, A. J., Carmody, T., & Reimitz, P. (2000) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.79 · Cited by 427 · cited 1×
“Another useful approach is to use outcome measures that can be administered in both clinician- and patient-rated forms, as in the case of the Inventory of Depressive Symptomatology (IDS) [”
MethodThe Hamilton Depression Scale: EVALUATION OF OBJECTIVITY USING LOGISTIC MODELS
Bech, P., Allerup, P., Gram, L. F., Reisby, N., Rosenberg, R., Jacobsen, O., & Nagy, A. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00676.x · Cited by 425
Effectiveness of St John's Wort in Major Depression: A Randomized Controlled Trial
Shelton, R. C., Keller, M. B., Gelenberg, A., Dunner, D. L., Hirschfeld, R., Thase, M. E., Russell, J., Lydiard, R. B., Crits-Christoph, P., Gallop, R., et al. (2001) · JAMA · doi:10.1001/jama.285.15.1978 · Cited by 382
Research works printed but not linked: 2
- 10.1001/jama.271.24.1940 · doi:10.1001/jama.271.24.1940 · Paper page
- 10.1037//0022-006x.70.4.887 · doi:10.1037//0022-006x.70.4.887
Cited by
Items 301–400 of 460
Trial designs advance to overcome bitter pill of placebo effect
Heger, M. (2013) · Nature Medicine · doi:10.1038/nm1113-1353 · Cited by 6
A novel artificial intelligence-based methodology to predict non-specific response to treatment
Guidetti, C., D, M. F. M., Manfredi, P. L., Pappagallo, M., & Goméni, R. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116506 · Cited by 5
The plan of enrichment designs for dealing with high placebo response
Zhang, X., Chen, Y., & Tamura, R. (2017) · Pharmaceutical Statistics · doi:10.1002/pst.1833 · Cited by 5
“Here we advocate another assignment mechanism that requires randomization at the beginning of stage 1 and rerandomization at the beginning of stage 2, as described in Fava et al[2] and emphasized by Chen et al.[20] This assignment facilitates statistical analysis on continuous endpoint since the rerandomization ensure…”
MethodInfluentialGaebel, C., Jarczok, M. N., Aguilar‐Raab, C., Rittner, S., Warth, M., Stoffel, M., & Ditzen, B. (2025) · Stress and Health · doi:10.1002/smi.70026 · Cited by 7
“…add‐on therapy design offers advantages such as targeted approaches for non‐responders and reduced bias when properly randomised, but it also presents challenges such as increased complexity, potential over-estimation of benefits, and limited generalisability (Fava et al. 2003; Gold et al. 2011).”
Homma, G., & Daimon, T. (2018) · Pharmaceutical Statistics · doi:10.1002/pst.1913 · Cited by 5
“T = wβ1 + (1 − w)β2 √ w2Var(β1) + 2w(1 − w)Cov(β1, β2) + (1 − w)2Var(β2) , (3)”
Comparison of novel methods in two‐way enriched clinical trial design
Liu, Y., Rybin, D. V., Heeren, T., & Doros, G. D. (2019) · Statistics in Medicine · doi:10.1002/sim.8288 · Cited by 5
“At Stage I: Equation (1): ΔY1i = α01 + α11Y1i + δ1G1i + ε1i; i = 1 ∶ N, where ΔY1i is the change in outcome from baseline to the end of Stage I.”
BackgroundMethodInfluentialGoméni, R., Bressolle, F., & D, M. F. M. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115367 · Cited by 5
“, 2022), and the two stages sequential parallel comparison designs (Fava et al., 2003; Chen et al. 2011).”
Merlo‐Pich, E., Bettica, P. U., & Goméni, R. (2009) · The Open Psychiatry Journal · doi:10.2174/1874354400903010020 · Cited by 5
Borba, C. P. C. (2014) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2014/10473 · Cited by 5
“The Sequential Parallel Comparison Design (SPCD) provides the greatest power to detect an effect of folate and vitamin B12 within the limits of the sample sizes that can be realistically achieved through the collaborative and funding limitations[33].”
BackgroundEarly treatment response affects signal detection in a placebo-controlled depression study
Targum, S. D., & Catania, C. J. (2017) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2017.10.001 · Cited by 5
A commentary on: statistical inference problems in sequential parallel comparison designs
Schoenfeld, D., Doros, G. D., & D, M. F. M. (2019) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2019.1584207 · Cited by 5
“…to placebo in populations that do not typically reflect real clinical practice, in the hope that the drug will be more active than a placebo by participating in a study whichmay be therapeutic in itself for a myriad of reasons, including support, encouragement, and expectations (Fava et al. 2003).”
BackgroundMethodResultSelf-citationWiener, L. E., Ivanova, A., Li, S., Silverman, R. K., & Koch, G. G. (2019) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2019.1633660 · Cited by 5
“Fava et al. (2003) propose the sequential parallel comparison design (SPCD) as a modification of the placebo lead-in design.”
MethodThe Placebo Response in Adult ADHD as Objectively Assessed by the TOVA Continuous Performance Test
Rotem, A., Ben-Sheetrit, J., Newcorn, J. H., Danieli, Y., Peskin, M., Golubchik, P., Ben‐Hayun, R., Weizman, A., & Manor, I. (2020) · Journal of Attention Disorders · doi:10.1177/1087054719897819 · Cited by 5
“…trials (the randomized placebo-control paradigm), and some have suggested that the increasing PR over the years has hindered our ability to aptly detect and employ novel therapeutic strategies (Ben-Sheetrit et al., 2018; Fava et al., 2003), although this is controversial (Khan et al., 2017).”
BackgroundPower calculations for the sequential parallel comparison design with continuous outcomes
Ivanova, A., & Qaqish, B. F. (2020) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2020.1818252 · Cited by 5
“For the continuous endpoint, Tamura and Huang (2007) considered the test statistic formed based on a linear combination of the estimated treatment effects as in Fava et al. (2003).”
MethodBest, S. R. D. (2014) · Activitas Nervosa Superior · doi:10.1007/bf03379605 · Cited by 5
Exposure–Response modeling of anti-depressant treatments: the confounding role of placebo effect
Goyal, N., & Goméni, R. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9290-0 · Cited by 5
“Furthermore, placebo response has been recognized as a key factor in determining the failure of RCTs in depression with an increasing magnitude in the effect over the years [6–9].”
BackgroundZimmerman, M. A. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.115.178871 · Cited by 5
Jha, M. K., Ghitza, U. E., SHOPTAW, S. J., Minhajuddin, A., Kuruvila, S., Wakhlu, S., Nunes, E. V., Schmitz, J. M., Coffin, P. O., Bart, G. B., et al. (2025) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.25m15825 · Cited by 5
Smalt, C. J., Sugai, J. A., Koops, E. A., Jahn, K. N., Hancock, K. E., & Polley, D. B. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00675-w · Cited by 4
Natarajan, P., Menounos, S., Harris, L. A., Monuja, M., Gorelik, A., Karjalainen, T., Buchbinder, R., Harris, I. A., Naylor, J., & Adie, S. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-080258 · Cited by 4
Zonisamide for Bipolar Depression: A Randomized, Double Blind, Placebo-Controlled, Adjunctive Trial
Dauphinais, D., Knable, M. B., Rosenthal, J., Polanski, M., & Rosenthal, N. E. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4065 · Cited by 4
Sample size re-estimation and other midcourse adjustments with sequential parallel comparison design
Silverman, R. K., & Ivanova, A. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1289951 · Cited by 6
“The sequential parallel comparison design (SPCD) was developed to combat the issue of large placebo response that can occur in traditional randomized clinical trials (Fava et al., 2003).”
MethodAntidepressant effect in older depressed patients: the lessons of two agomelatine trials
Goodwin, G. M., Thomas, P., Heun, R., Boyer, P., Picarel-Blanchot, F., & de Bodinat, C. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000174 · Cited by 4
Rejoinder to “Statistical inference problems in sequential parallel comparison designs”
Cui, Y., Ogbagaber, S., & Hung, H. (2019) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2019.1609017 · Cited by 4
“Removing placebo responders at the end of the first stage, proposed in the initial paper Fava et al. (2003), substantially reduces the placebo response rate and in effect might make it easier to detect treatment difference.”
BackgroundModel‐Informed Approach to Assess the Treatment Effect Conditional to the Level of Placebo Response
Goméni, R., Rabinowitz, J., Goyal, N., Bressolle, F., & D, M. F. M. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1584 · Cited by 4
“Among the different approaches for optimizing RCTs, the sequential parallel comparison design has also been proposed to reduce both placebo response and sample size.(8,11) Recently, a band-pass filter analysis strategy was proposed as a way to control the excessively high/low placebo response rates and thereby to enha…”
MethodJiao, F., Chen, Y., Min, M., & Jiménez, S. (2022) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2021.2011906 · Cited by 4
“Scenario 3: SPCD trial under platform setting SPCD, a two-stage design, has been proposed to handle high placebo response rates in psychiatry clinical trials (Y.-F. Chen et al. 2011; Chi et al. 2016; Fava et al. 2003; Tamura et al. 2011).”
MethodInnovation and placebos in research: a new design of clinical trial
Holbrook, A. M., & Goldsmith, C. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15147-1 · Cited by 4
Dose Finding With the Sequential Parallel Comparison Design
Wang, J. J., & Ivanova, A. (2014) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2014.924960 · Cited by 4
“Binary and continuous outcomes can be analyzed by using a test statistic based on the linear combination of treatment effects from the two SPCD stages as proposed by Fava et al. (2003) and Chen et al. (2011), respectively.”
BackgroundMethodBialosky, J. E., & Robinson, M. E. (2017) · Journal of Manual & Manipulative Therapy · doi:10.1080/10669817.2017.1298699 · Cited by 4
“Furthermore, researchers often view placebo as an annoyance capable of confounding study results [3,4].”
BackgroundFlibanserin – the female Viagra?
Shapiro, D. N., Stevens, D. M., & Stahl, S. M. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1315138 · Cited by 4
“In trials of major depressive disorder, that number can reach as high as 52% (Fava et al. 2003).”
BackgroundHunting for Peripheral Biomarkers to Support Drug Development in Psychiatry
Domenici, E., Muglia, P., & Pich, E. M. (2008) · Springer eBooks · doi:10.1007/978-0-387-79251-4_16 · Cited by 4
Liu, X., Kim, C., Han, Z., Lim, P., Roychoudhury, S., D, M. F. M., & Doros, G. D. (2022) · Statistics in Medicine · doi:10.1002/sim.9349 · Cited by 3
“In addition to Equations (3) and (4), to account for the lack of identifiability for the treatment effect of each stratum, we now introduce two sensitivity parameters β1 and β2, denoting the extent of deviation from the two aforementioned mixture strata in the drug and placebo groups respectively, that are: β1 = E[Y1|…”
BackgroundMethodQuan, H., Chen, X., Luo, J., & Chen, X. (2022) · Statistics in Medicine · doi:10.1002/sim.9381 · Cited by 4
Using Placebo Response to Pain as a Predictor of Placebo Response in Mood Disorders
Costi, S., Collins, K. A., Davidson, M., & Iosifescu, D. V. (2016) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-016-0092-3 · Cited by 3
Ivanova, A., Zhang, Z., Thompson, L., Yang, Y., Kotz, R. M., & Fang, X. (2015) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2015.1092028 · Cited by 3
“The data from the two stages is pooled by combining the estimated treatment effects from the two stages (Fava et al., 2003; Chen et al., 2011) or by combining test statistics from Stage 1 and Stage 2 (Liu et al., 2012).”
BackgroundMethodLiu, Y. (2016) · Communication in Statistics- Theory and Methods · doi:10.1080/03610926.2016.1205613 · Cited by 3
“Simulation results under assumed conditional independence In the normal-normal case, with 0.8 for power 1-β , 0.6 for weight w, and 10 for the mean difference between treatment groups for both periods, the sample size for SPD is 107 (Table 1), while the sample size for traditional parallel-group design is 126.”
MethodInfluentialPsychopharmacology and Psychotherapy Research
Kim, K., & Jeon, H. J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9721-0_16 · Cited by 3
Pharmacokinetic and Pharmacodynamic Modeling
Kalaria, S. N., Wang, H., & Gobburu, J. V. S. (2020) · Springer eBooks · doi:10.1007/978-3-319-52677-5_284-1 · Cited by 3
A double-blind study of empathic support and expectation as mechanisms of symptom change
Thomas, J. G., Sharp, P. B., Niznikiewicz, M. A., & Heller, W. (2021) · Psychotherapy Research · doi:10.1080/10503307.2021.1909770 · Cited by 5
“…are truly additive (Fava et al., 2017;Kirsch, 2000), attempts tominimize placebo effects in clinical trials and maximize them in clinical practice (Fava et al., 2003), and studies disaggregating andquantifying the role of various contextual factors (Howe et al., 2017; Kaptchuk et al., 2008) all…”
BackgroundNovel Study Designs for Clinical Trials in Mood Disorders
Jeon, H. J., & D, M. F. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-405170-6.00008-7 · Cited by 3
Khan, A., Atkinson, S. D., Mezhebovsky, I., She, F., Leathers, T., & Pathak, S. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4062 · Cited by 4
Neural Predictors of the Antidepressant Placebo Response
Rette, D. N., McDonald, E., Iosifescu, D. V., & Collins, K. A. (2019) · Pharmaceuticals · doi:10.3390/ph12040158 · Cited by 3
“severity, comorbid anxiety) and modified inclusion and exclusion criteria accordingly [6], with the aim of preventing likely placebo responders from entering the pool of randomized clinical trial participants.”
BackgroundTriple‐Uptake Inhibitors (Broad‐Spectrum Antidepressants)
Skolnick, P. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch18 · Cited by 4
Pharmacokinetic and Pharmacodynamic Modeling
Kalaria, S. N., Wang, H., & Gobburu, J. V. S. (2022) · Springer eBooks · doi:10.1007/978-3-319-52636-2_284 · Cited by 3
Placebos in Schizophrenia Research: An Historical Overview and Introduction to Ethical Issues
Berkhout, S. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac051 · Cited by 3
“24 And while it is often assumed that a high placebo response rate means that the efficacy signal for a new treatment will be hampered or diminished, 25 a second challenge to reconcile has been the finding that the placebo response is often intermingled with a drug treat-ment response.”
BackgroundMethods to improve the efficiency of confirmatory clinical trials
Boessen, R. (2013) · Utrecht University Repository (Utrecht University) · Cited by 3
How can we make measures of psychotic depression symptoms more clinically useful?
Fava, M. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12177 · Cited by 3
“For example, half of the studies of approved pharmacological treatments for depression have failed to detect a significant effect over placebo, and the effect sizes have typically been quite modest on average (12).”
BackgroundRegulation of complementary medicines
Harvey, K. J. (2017) · Internal Medicine Journal · doi:10.1111/imj.13548 · Cited by 3
Li, Q., Detke, M. J., Paul, S. M., Potter, W. Z., Zhang, F., Breier, A. F., Alphs, L. D., Wolkowitz, O. M., Ereshefsky, L., Grecco, G. G., et al. (2025) · medRxiv · doi:10.1101/2025.05.29.25328167 · Cited by 3
Jha, M. K., Ghitza, U. E., Carmody, T. J., Kuruvila, S., SHOPTAW, S. J., Minhajuddin, A., Wakhlu, S., Schmitz, J. M., Coffin, P. O., Bart, G. B., et al. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001538 · Cited by 2
Quan, H., Xu, Z., & Chen, X. (2026) · Statistics in Medicine · doi:10.1002/sim.70382 · Cited by 2
Design Archetypes for Phase 2 Clinical Trials in Central Nervous System Disorders
Mallinckrodt, C. H., Detke, M. J., Prucka, W. R., Ruberg, S. J., & Molenberghs, G. (2010) · Drug Information Journal · doi:10.1177/009286151004400406 · Cited by 2
Baseline reliability and early response in clinical trials of major depressive disorder
Targum, S. D. (2020) · Medical Research Archives · doi:10.18103/mra.v8i10.2241 · Cited by 2
“The reliability of the baseline measurement has been challenged by several investigators (5-6,14-16).”
BackgroundLack of Efficacy of Suvorexant in People with Insomnia and Poorly Controlled Type 2 Diabetes
Winkelman, J. W., Wipper, B., Zackon, J., & Hoeppner, B. B. (2023) · Nature and Science of Sleep · doi:10.2147/nss.s434058 · Cited by 2
Okafor, C. N., Carmody, T. J., Stotts, A. L., Bart, G. B., Mayes, T. L., Karns-Wright, T., Trivedi, M. H., SHOPTAW, S. J., & Potter, J. S. (2024) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2024.100230 · Cited by 2
“The trial employed a sequential parallel comparison design (SPCD) (Fava et al., 2003) in which study participants were randomized in a 1:3 ratio during the first 6-weeks to receive NTX-BUP or placebo (Stage 1).”
MethodShan, G., & Zhang, Y. (2024) · Journal of Applied Statistics · doi:10.1080/02664763.2024.2385997 · Cited by 2
“They provided the simplified formula of D VD using the software Mathematics, Then the linear combination (LC) test is presented as which asymptotically follows the standard normal distribution when there is no difference between a drug and placebo [7,12].”
InfluentialEstimating Causal Treatment Effects in the Sequential Parallel Comparison Design (SPCD)
Song, Y., D, M. F. M., Kim, C., Yeh, R. W., & Doros, G. D. (2025) · Statistics in Medicine · doi:10.1002/sim.70319 · Cited by 2
Farrar, J. (2014) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12081_4 · Cited by 2
“…to minimize the placebo response include standardizing recruitment to be inclusive of patients with varying severity and longevity of disease symptoms; staff training, controlling patient’s expectations; longer studies, and excluding patients likely to be placebo responders (Fava et al., 2003).”
BackgroundSubject Numbers and Placebo Outcome Variability in Clinical Trials of New CNS Medications
Ridgway, D., Khan, A., Ridgway, G., Cierpial, M. A., & Lineberry, C. G. (2007) · Drug Information Journal · doi:10.1177/009286150704100602 · Cited by 2
“(5), where an adjustment was made to account for publication bias.”
BackgroundSkouteris, D. M. G. (2013) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000305 · Cited by 2
“neuropathic pain is a condition where a new active medication may not necessarily be superior to existing treatment and to placebo [14].”
BackgroundAntidepressant Trials: Are the Diminishing Effect Sizes of Efficacy Trials Avoidable?
Rickels, K., & Robinson, D. S. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000796 · Cited by 2
Lui, K. (2018) · Statistical Methods in Medical Research · doi:10.1177/0962280218796255 · Cited by 2
Sequential parallel comparison design with two coprimary endpoints
Homma, G., & Daimon, T. (2019) · Pharmaceutical Statistics · doi:10.1002/pst.1987 · Cited by 2
“For cases A, B, and C, we considered two scenarios where the standard deviations were equal across both stages, that is, (σ1,1, σ2,1, σ1,2, σ2,2) = (15, 15, 6, 6) (scenario 1) and where the standard deviations at stage 2 were smaller than those at stage 1, that is, (σ1,1, σ2,1, σ1,2, σ2,2) = (15, 12, 6, 4) (scenario 2…”
MethodInterventionsdesign, Evaluationsverfahren und Wirksamkeit von Interventionen
Reis, D., & Meier, L. L. (2021) · Springer eBooks · doi:10.1007/978-3-658-28654-5_24-1 · Cited by 2
Tsuchida, J., Miyauchi, Y., Ando, S., & Sozu, T. (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2021.1924257 · Cited by 2
“The sequential parallel comparison design (SPCD) framework (Fava et al. 2003; Fava and Shoenfeld 2010a,b, 2011, 2012a,b,c) has been proposed to address this issue.”
MethodNasser, A. F., Goméni, R., Wang, Z., Hull, J. T., Busse, G. D., Melyan, Z., D, M. F. M., O’Neal, W., & Rubin, J. S. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15412 · Cited by 2
Randomized Discontinuation Trials
Fedorov, V. V. (2022) · Springer eBooks · doi:10.1007/978-3-319-52636-2_104 · Cited by 2
Placebo effects and research quality: What is good evidence?
Jonas, W. B., Goldman, D. A., Muhammed, S., Mullins, C. D., & Colloca, L. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197645444.003.0022 · Cited by 2
Pharmacotherapy of postpartum depression: current practice and future directions
Tcheremissine, O. V., & Lieving, L. M. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.12.1999 · Cited by 2
“Between 30 and 50% of depressed patients in clinical trials have substantial reduction in symptoms during treatment with placebo [56,57].”
BackgroundSmith, S. M., Fava, M., Jensen, M. P., Mbowe, O. B., McDermott, M., Turk, D. C., & Dworkin, R. H. (2019) · Journal of Pain · doi:10.1016/j.jpain.2019.09.008 · Cited by 2
RetractedKowalewski, E. K., Preisser, J. S., & Koch, G. G. (2024) · Springer eBooks · doi:10.1007/978-3-031-65937-9_11 · Cited by 1
Carmody, T. J., Mayes, T. L., Jha, M. K., SHOPTAW, S. J., & Trivedi, M. H. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001533 · Cited by 1
Placebo Responses in Trials for Multiple Sclerosis
Gilio, L., Centonze, D., & Bassi, M. S. (2025) · Neurologic Clinics · doi:10.1016/j.ncl.2025.08.004 · Cited by 1
Placebo Effects in the Treatment of Depression—Implications for the Psychedelic Renaissance
Ansari, M., Elliot, S. I., Holmes, S. E., & Sanacora, G. (2025) · Neurologic Clinics · doi:10.1016/j.ncl.2025.08.009 · Cited by 1
Minimizing placebo responses in clinical trials
Emborg, C., Kothari, S. F., Finnerup, N. B., & Vase, L. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-29884-4.00018-2 · Cited by 1
Guidetti, C., Giorgi, R. D., Huneke, N. T. M., Crescenzo, F. D., Zippi, C., Papakostas, G. I., & D, M. F. M. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20251233 · Cited by 1
Novel pharmacotherapies for opioid use disorder and opioid withdrawal
Shen, M. R., Owusu-Boaitey, K. E., Murphy, Z., Rains, A., Wang, P. R., Zhou, D. W., & Suzuki, J. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1909149 · Cited by 1
“Given small samples and high placebo response, the sequential parallel comparison design, which re-randomizes placebo non-responders and pools across phases, offers improved ef fi ciency (75).”
Dar, M. A., & Wani, R. A. (2015) · International Journal of Emergency Mental Health and Human Resilience · doi:10.4172/1522-4821.1000209 · Cited by 1
“antidepressant therapy do not achieve timely remission (John Rush et al., 2006; Fava et al., 2003).”
BackgroundThe Role of Psychotherapy in the Management of Treatment‐resistant Depression
Thase, M. E. (2013) · Wiley eBooks · doi:10.1002/9781118556719.ch8 · Cited by 6
Mallinckrodt, C. H., Detke, M. J., Prucka, W. R., Ruberg, S. J., & Molenberghs, G. (2010) · Drug Information Journal · doi:10.1177/009286151004400408 · Cited by 1
A Regulatory Perspective on Clinical Trials: FDA 101 for Clinicians
Farchione, T. R. (2013) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.2013.18.3.4 · Cited by 1
Why antidepressant clinical trials fail: the role of expectations
Sinyor, M., Schaffer, A., & LEVITT, A. J. (2011) · Clinical Investigation · doi:10.4155/cli.11.109 · Cited by 1
Wang, G., Mcintyre, A., Earley, W., Raines, S., & Eriksson, H. (2012) · Psychopharmacology bulletin · doi:10.64719/pb.4057
Zhang, P. G. Y., Carroll, K., Hobart, M., Augustine, C., & Koch, G. G. (2017) · Pharmaceutical Statistics · doi:10.1002/pst.1839 · Cited by 1
“In the original SPCD design, there is no placebo run‐ in; rather, the design is conducted in 2 stages.([12]) At the outset, patients are randomized to one of 3 treatment sequences being placebo‐placebo, placebo‐drug, and drug‐drug, where the first 2 sequences are allocated a proportionately higher number of subjects t…”
MethodNotes on Use of the Odds Ratio under the Sequential Parallel Comparison Design with Binary Outcomes
Lui, K. (2018) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2018.1497530 · Cited by 1
“Because the placebo response rate for most major depressive disorder ranges, as noted by Fava et al. (2003), from around 35% to 45%.”
BackgroundMethodInfluentialExact and asymptotic tests under the sequential parallel comparison design
Lui, K. (2018) · Pharmaceutical Statistics · doi:10.1002/pst.1894 · Cited by 1
Repeated Measures Analysis of the Sequential Parallel Comparison Design With Normal Responses
Lu, K., & Du, Y. (2020) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2020.1860120 · Cited by 1
“The sequential parallel comparison design (SPCD) was proposed by Fava et al. (2003) as a means to address high placebo response in psychiatric clinical trials.”
MethodInfluentialZaharia, S., & Horoșan, L. (2021) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2021.4.3 · Cited by 1
“Based on a set of practical consideration addressing each of these issues, the authors have proposed the “Sequential Parallel Comparison Design” - SPCD, a methodology adapted for the investigation of psychiatric treatments [82,89].”
InfluentialChallenges and proposed solutions to conducting Alzheimer’s disease psychosis trials
Ballard, C. G., Tariot, P. N., Soto‐Martin, M., Pathak, S. S., & Liu, I.-Y. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1384176 · Cited by 2
“Another option is to use the sequential parallel comparative design (SPCD), which was developed to minimize placebo responses (29).”
BackgroundMethodInfluentialGanapathiraju, M. K., Bhatia, T., Deshpande, S., Wesesky, M. A., Wood, J. A., & Nimgaonkar, V. L. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.06.022 · Cited by 1
Shan, G., Lu, X., Zhang, Y., & Wu, S. S. (2024) · Statistical Papers · doi:10.1007/s00362-024-01606-5 · Cited by 1
“The original SPCD compares a treatment and placebo in two phases (Fava et al. 2003; Ivanova et al. 2011; Chen et al. 2011; Ivanova and Tamura 2015).”
InfluentialA note on the probability structure of a doubly randomized delayed start design
Yang, Z. (2025) · Statistical Theory and Related Fields · doi:10.1080/24754269.2025.2457279 · Cited by 1
“A novel sequential parallel comparison design (SPCD) framework, which was aimed at increasing the efficiency of placebo-controlled psychiatric clinical trials, was proposed by Fava et al. (2003) to address this issue of high placebo response rate.”
Zadegan, S. A., Calderon, O., Karagas, N. E., Patino, J., Dongarwar, D., Duncan, B., Teixeira, A. L., Rocha, N. P., & Furr-Stimming, E. E. (2026) · Journal of Huntington s Disease · doi:10.1177/18796397251411112 · Cited by 1
Novel Approaches to Study Design and Intervention for Residual Symptoms of MDD
Mischoulon, D. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14com09451 · Cited by 1
Ivanova, A., & Tamura, R. (2013) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2012.738750 · Cited by 1
“Fava et al. (2003) described the novel strategy using two different formats.”
MethodToniolo, R. A. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2016.tde-07122016-150647 · Cited by 2
Using Psychiatric Rating Scales in Clinical Trials: A Proposal
Ghaemi, S. N. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001220 · Cited by 1
“For the concentration item, the correlating landmarks are “occasional difficulties in collecting one's thoughts” (2), “difficulties in concentrating or sustaining thoughts which influences the ability to read or hold a conversation” (4), and “unable to read or converse without great difficulty” (6).”
BackgroundPathways to Treatment Development
Jones, N. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819641-0.00121-3 · Cited by 1
Holbrook, A. M., Goldsmith, C. H., & Leung, M. (2008) · Wiley eBooks · doi:10.1002/9781118445112.stat07062 · Cited by 1
Kowalewski, E. K. (2023) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/0cnz-s675 · Cited by 1
Metadata
- Authors
- Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A.
- Affiliations
- Harvard University (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 72
- Issue
- 3
- Pages
- 115-127
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2073526412
- Cited by
- 452
- References
- 34
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 17 · 2023: 18 · 2022: 21 · 2021: 16 · 2020: 29 · 2019: 41 · 2018: 23 · 2017: 32 · 2016: 21 · 2015: 29 · 2014: 22 · 2013: 21 · 2012: 22
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- placebo response, placebo effect, mental illness, clinical trial design, regression to the mean, attrition, sample size reduction, outcome measure sensitivity
- MeSH terms
- Mental Disorders, Clinical Trials as Topic, Double-Blind Method, Humans, Research Design, Reproducibility of Results, Placebo Effect
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.